C3N-02090
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 61.41546886
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.390
- PROTEIN_SECRETION+0.330
- IL6_JAK_STAT3_SIGNALING+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
- INTERFERON_ALPHA_RESPONSE+0.290
- ALLOGRAFT_REJECTION+0.260
- COMPLEMENT+0.260
- INFLAMMATORY_RESPONSE+0.250
- TNFA_SIGNALING_VIA_NFKB+0.250
- OXIDATIVE_PHOSPHORYLATION+0.240
Top 10 suppressed
- E2F_TARGETS-0.600
- MYC_TARGETS_V2-0.600
- G2M_CHECKPOINT-0.570
- MYC_TARGETS_V1-0.420
- MITOTIC_SPINDLE-0.310
- CHOLESTEROL_HOMEOSTASIS-0.210
- APICAL_SURFACE-0.170
- SPERMATOGENESIS-0.160
- UNFOLDED_PROTEIN_RESPONSE-0.160
- DNA_REPAIR-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10900573 | — | — | 0.856 |
| 2 | SRR8518195 | — | A | 0.839 |
| 3 | TCGA-PA-A5YG-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.833 |
| 4 | TCGA-BH-A0EB-01A-11R-A034-07 | — | B | 0.832 |
| 5 | MDT-AP-3274 | Med | Medulloblastoma | 0.831 |
| 6 | TCGA-DQ-5630-01A-01R-1873-07 | — | — | 0.831 |
| 7 | SRR8518419 | — | A | 0.827 |
| 8 | BS_Z0AVVB1V | pilocytic astrocytoma | — | 0.824 |
| 9 | BS_S50KQEXV | low-grade glioma | — | 0.821 |
| 10 | SRR8518268 | — | A | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.290 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.260 | Idelalisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.190 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| MYOGENESIS | 0.150 | Inavolisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |